← back to search

Liru Li

Harbin Medical University · CN
Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Medicine, Breast cancer, Internal medicine, Cancer research, Oncology, and Mesenchymal stem cell.
h-index
citations
291
works
21
NIH funding
primary concept
email

Recent publications

A Lamp2a-linked RNA secreted by ADSCs prevents ENO1–lactylation–glycolysis feedback and cell malignant behavior in triple-negative breast cancer
Cell Death and Disease 2026cited by 1position: middledoi
Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass
Annals of Hematology 2025cited by 2position: middledoi
Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer
British Journal of Cancer 2025cited by 1position: middledoi
TPTEP1 impedes the reprogramming of fatty acid metabolism in triple negative breast cancer via miR-1343-3p/SIRT3 axis
International Journal of Biological Macromolecules 2024cited by 10position: lastdoi
Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy
BMC Cancer 2024cited by 9position: lastdoi
Pyroptotic macrophages promote proliferation and chemotherapy resistance of <scp>peripheral T‐cell lymphoma</scp> via <scp>TLR4</scp> signaling pathway
Cancer Science 2024cited by 7position: middledoi
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.
Journal of Clinical Oncology 2024cited by 4position: middledoi
Construction of a nano-fluorescent polymer drug delivery system for breast cancer treatment
Journal of Molecular Structure 2024cited by 3position: lastdoi
High PPP4C expression predicts poor prognosis in diffuse large B-cell lymphoma
Clinical and Experimental Medicine 2024cited by 2position: middledoi
The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma
Clinical & Translational Oncology 2024cited by 2position: middledoi
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine
BMC Cancer 2022cited by 11position: firstdoi
Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters
BMC Cancer 2021cited by 19position: middledoi
High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study
BMC Pharmacology and Toxicology 2021cited by 7position: middledoi
High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin : a retrospective study
Research Square 2021cited by 1position: middledoi
High Expression of Plakoglobin Promotes Metastasis in Invasive Micropapillary Carcinoma of the Breast via Tumor Cluster Formation
Journal of Cancer 2019cited by 38position: middledoi
Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma
Cellular Physiology and Biochemistry 2018cited by 44position: middledoi
IFN<i>α</i>-Expressing Amniotic Fluid-Derived Mesenchymal Stem Cells Migrate to and Suppress HeLa Cell-Derived Tumors in a Mouse Model
Stem Cells International 2018cited by 17position: middledoi
Systemic immune response associated with radiation therapy in B‑cell non‑Hodgkin's lymphoma of Waldeyer's ring
Oncology Reports 2018cited by 3position: middledoi
Characteristics of Human Endometrium-Derived Mesenchymal Stem Cells and Their Tropism to Endometriosis
Stem Cells International 2017cited by 49position: middledoi
MicroRNA-194 promotes the growth, migration, and invasion of ovarian carcinoma cells by targeting protein tyrosine phosphatase nonreceptor type 12
OncoTargets and Therapy 2016cited by 35position: middledoi
Characteristics of Human Amniotic Fluid Mesenchymal Stem Cells and Their Tropism to Human Ovarian Cancer
PLoS ONE 2015cited by 26position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Xingjian Niu · Harbin Medical University7 papers (2018–2024)Dabei Tang · Harbin Medical University5 papers (2021–2025)Qingyuan Zhang · Heilongjiang Institute of Technology4 papers (2018–2025)Xiaoyu Shan · Massachusetts Institute of Technology3 papers (2021–2021)Jingtong Li · Shandong University of Technology3 papers (2018–2019)Qijia Xuan · Harbin Medical University3 papers (2018–2019)Hongfei Ji · Harbin Medical University3 papers (2018–2019)Hongbin Li · Georgetown University3 papers (2024–2025)Tian Liang · Soochow University3 papers (2015–2018)Yue Yang · Harbin Medical University3 papers (2018–2019)Lan Huang · 81th Hospital of PLA3 papers (2018–2019)Qingyuan Zhang · Université Paris Cité3 papers (2021–2024)Lei Yin · Wuhan University of Science and Technology3 papers (2018–2019)Dejun Wang · Harbin Medical University3 papers (2015–2018)Yan Cheng · Harbin Medical University3 papers (2015–2018)Wenjia Su · Harbin Medical University3 papers (2018–2021)Wenhui Zhao · Sun Yat-sen University Cancer Center3 papers (2021–2025)Han Zhang · Tianjin University of Traditional Chinese Medicine3 papers (2018–2024)Ying Song · Nanchang University2 papers (2024–2025)Yue Zhang · Harbin Medical University2 papers (2024–2024)